Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Vova Ida Therapeutics Inc. currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This outstanding action is concentrated under 1 distinct examiner and 1 distinct art unit, indicating a focused prosecution effort at this stage. The lack of distribution across units suggests that the company's current patent activity is confined to a niche within the broader pharmaceutical landscape.
The busiest examiner for the portfolio is DAVIS, RUTH A, who is responsible for 1 busiest examiner pending action. Because this individual handles the entirety of the pending workload, the prosecution timeline for the company is currently dependent on the specific throughput and practices of the examiner. Practitioners should monitor the requirements of the art unit to ensure efficient responses to the pending matter. The alignment of the 1 pending action with the examiner simplifies the administrative tracking for the portfolio, as there are no competing deadlines across different examiners or art units at this time. This focus allows the company to dedicate its resources to resolving the specific concerns of the 1 art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DAVIS, RUTH A | 1 | 60.9% | +31.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18252798 | NICOTINAMIDE DINUCLEOTIDE (NAD) DETECTION AND QUANTIFICATION | DAVIS, RUTH A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18252798 | NICOTINAMIDE DINUCLEOTIDE (NAD) DETECTION AND QUANTIFICATION | DAVIS, RUTH A | — |
| Art Unit | Apps |
|---|---|
| 1699 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18252798 | NICOTINAMIDE DINUCLEOTIDE (NAD) DETECTION AND QUANTIFICATION | DAVIS, RUTH A | 1699 | §101§102§112Other | Non-Final OA | — | Pending | May 12, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialVova Ida Therapeutics Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Ruth A Davis has the most, with 1 of Vova Ida Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
